



National Foundation
for Cancer Research
We Make Cures Possible

NFCR Global Summit and Award Ceremonies

for Cancer Research & Entrepreneurship

FRIDAY OCTOBER 18, 2024

The National Press Club
529 14th St NW, Washington, DC 20045



Interact with Leading Cancer Scientists, Entrepreneurs & Survivors
MISSION-DRIVEN IMPACT. A WORLD WITHOUT CANCER IS POSSIBLE.



National Foundation
for Cancer Research
We Make Cures Possible

JOIN THE GLOBAL EFFORT TO CURE CANCER:

YOUR PARTNERSHIP CAN MAKE A LIFE-SAVING IMPACT

The **National Foundation for Cancer Research (NFCR)** is at the forefront of a global network dedicated to curing cancer. Since 1973, NFCR has provided over \$415 million in funding for cutting-edge cancer research, prevention, and public education. By collaborating with leading organizations and top scientists worldwide, NFCR drives game-changing discoveries in detection, treatments, and prevention. Our focus on “high-risk, high-reward” research often overlooked by other major funders has led to life-saving breakthroughs that benefit patients today.

Your support can accelerate the next big breakthrough. Partner with NFCR and make a direct impact on the future of cancer research. Together, we can transform innovative ideas into life-saving solutions and bring us closer to a cure. Join our mission and be part of the global effort to end cancer.

**COMMIT TO PROGRESS IN CANCER RESEARCH
AND HELP SHAPE THE FUTURE OF CANCER CARE.**



NFCR.org

THE GLOBAL NETWORK
COLLABORATION TO CURE CANCER



Part I: New Frontiers for Cancer Research

8:45 AM – 9:00 AM

WELCOME REMARKS

Sujuan Ba, Ph.D.

CEO of NFCR and Co-Founder of AIM-HI Accelerator Fund

Webster K. Cavenee, Ph.D.

*Chair of the Scientific Advisor Board of NFCR and UCSD Distinguished Professor Emeritus,
University of California San Diego*



Sujuan Ba, Ph.D.



Webster K. Cavenee, Ph.D.

9:00 AM – 9:30 AM

KEYNOTE PRESENTATION

Drew Pardoll, M.D., Ph.D.

*Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy,
Johns Hopkins University School of Medicine*



Drew Pardoll, M.D., Ph.D.

Part I: New Frontiers for Cancer Research

9:30 AM – 10:30 AM

SESSION I

NEW APPROACHES TO CANCER TREATMENTS

MODERATOR: Lisa Coussens, Ph.D. *Oregon Health & Science University*

PANELISTS:

Aditya Bardia, M.D., *University of California, Los Angeles*

Jonathan Chernoff, M.D., Ph.D., *Fox Chase Cancer Center*

Paul Mischel, M.D., *Stanford University*

Scott Lippman, M.D., *University of California, San Diego*

10:30 AM – 11:00 AM COFFEE BREAK



Lisa Coussens, Ph.D.



Aditya Bardia, M.D.



Jonathan Chernoff, M.D., Ph.D.



Paul Mischel, M.D.



Scott Lippman, M.D.

Part I: New Frontiers for Cancer Research

11:00 AM – 12:00 PM

SESSION II

EARLY DETECTION AND CANCER PREVENTION

MODERATOR: **Carlos Doti, M.D.**, *VP AstraZeneca, Head of Medical Affairs, US Oncology Business Unit*

PANELISTS:

Ajay Goel, Ph.D., *Beckman Research Institute of City of Hope*

Samir Hanash, M.D., Ph.D., *MD Anderson Cancer Center*

Steven Lipkin, M.D., Ph.D., *Weill Cornell Medicine*

Sapna Syngal, M.D., MPH, *Dana-Farber Cancer Institute*

12:00 PM – 12:30 PM INTERMISSION BREAK



Carlos Doti, M.D.



Ajay Goel, Ph.D.



Samir Hanash, M.D., Ph.D.



Steven Lipkin, M.D., Ph.D.



Sapna Syngal, M.D., MPH

Part II: Luncheon Award Ceremony

12:30 PM – 1:30 PM

AIM-HI BEACON AWARD CEREMONY

Honoring Margaret Foti, Ph.D., M.D. (hc)



EMCEE

Rose Wang, MBA

Board Director of AIM-HI Accelerator Fund; Founder & CEO of 1104Health

INTRODUCTION OF THE 2024 AIM-HI BEACON AWARD RECIPIENT



Sujuan Ba, Ph.D.

Co-Chair of 2024 AIM-HI Beacon Award Selection Committee

PRESENTING THE AIM-HI BEACON AWARD MEDALLION TO THE RECIPIENT



Webster K. Cavenee, Ph.D.

Co-Chair of 2024 AIM-HI Beacon Award Selection Committee

Part II: Luncheon Award Ceremony

2024 AIM-HI BEACON AWARD WINNER PRESENTATION



Margaret Foti, Ph.D., M.D. (hc)

CEO, American Association for Cancer Research

Dr. Margaret Foti is selected unanimously by the 2024 Blue Ribbon Selection Committee for her groundbreaking leadership and unwavering dedication to the advancement of cancer research, from a pool of outstanding global nominees.

Dr. Foti has served as the CEO of AACR for more than 42 years. During this time, she has led the growth and transformation of AACR from a relatively small professional association into the leading international scientific organization focused on basic, translational, and clinical cancer research. AACR currently has more than 59,000 members across 143 countries.

Throughout her career, Dr. Foti has been a powerful voice and advocate for women and underrepresented minority groups in science. As a result of her leadership, 45% of AACR members are women, 11% are from underrepresented minority groups, and 22% hail from countries with emerging economies.

In addition to expanding AACR's membership to include a diverse base of scientific professionals, Dr. Foti has actively engaged with the public and private sectors to foster advances in cancer science and medicine for the benefit of patients worldwide. One of the critical programs Dr. Foti helped found is the AACR Scientist <-> Survivor Program. Now in its 26th year, this unique program builds bridges and unity among the leaders of the scientific and cancer survivor and patient advocacy communities worldwide through communication and collaboration.

Under Dr. Foti's guidance, AACR has significantly expanded its portfolio of high-impact journals from one to 10 journals, which are instrumental in disseminating cutting-edge cancer research to the global scientific community. Dr. Foti's leadership was also instrumental in the publication of two landmark annual reports, the AACR Cancer Progress Report and the AACR Cancer Disparities Progress Report, which showcase how research continues to extend and improve lives and highlights the critical need for increased federal funding to accelerate the pace of progress against cancer.

Part II: Luncheon Award Ceremony

AIM-HI WOMEN'S VENTURE COMPETITION AWARD CEREMONY

INTRODUCTION OF THE 2024 WOMEN'S VENTURE COMPETITION WINNERS



Pamela Garzone, Ph.D.

*Co-Chair of the Competition Selection Committee;
Chief Development Officer of Anixa Biosciences*



Dimitra Georganopoulou, Ph.D.

*Co-Chair of the Competition Investment
Committee; General Partner of Qral Ventures*

2024 AIM-HI WOMEN'S VENTURE COMPETITION WINNERS AWARD PRESENTATIONS



First Prize with Distinction

Nabanita Nawar, Ph.D.

Co-Founder & CEO, HDAX Therapeutics



Second Prize

Paraskevi Giannakakou, Ph.D.

Co-Founder & CSO, ARMA Bio





Congratulations on being selected as the recipient of the prestigious
2024 AIM-HI BEACON AWARD FOR WOMEN LEADERS IN ONCOLOGY

MARGARET FOTI, PHD, MD (HC)
Chief Executive Officer
American Association for Cancer Research® (AACR)

Thank you for your significant contributions to cancer research and patient care. Under your visionary leadership, the AACR has become a leading international scientific organization with more than 59,000 members across 143 countries. Your commitment to accelerating the pace of discovery has improved the lives of patients worldwide.

AACR American Association
for Cancer Research®

AACR.ORG

CANCER RESEARCH SAVES LIVES®

Part III: Innovative Oncology Company Showcase and Investor Perspective

1:30 PM – 3:00 PM

WELCOME REMARKS

Matt Tremblay, Ph.D.

*Board Chair of AIM-HI Accelerator Fund
CEO of Blackbird Laboratories and Managing Director of Blackbird BioVentures*

SESSION I

INNOVATIVE ONCOLOGY COMPANIES SHOWCASE

ADVENTRIS PHARMACEUTICALS

Jenny Lesser Herbach, MBA, CEO

GEORGIAMUNE

Samir Khleif, M.D., CEO

CLASP THERAPEUTICS

Vipin Suri, Ph.D., CSO

DEGRON THERAPEUTICS

Lily Zou, Ph.D., MBA, CEO

BIOLOJIC DESIGN

Ronald Herbst, Ph.D., CMO

3:00 PM – 3:10 PM COFFEE BREAK



Matt Tremblay, Ph.D.



Jenny Lesser Herbach, MBA



Samir Khleif, M.D.



Vipin Suri, Ph.D.



Lily Zou, Ph.D., MBA



Ronald Herbst, Ph.D.

Part III: Innovative Oncology Company Showcase and Investor Perspective

3:10 PM – 4:10 PM

SESSION II INVESTOR PERSPECTIVE ON INNOVATIVE ONCOLOGY COMPANIES

MODERATOR: Matt Tremblay, Ph.D.

Dave Greenwald, Ph.D., *Vice President Business Development, Deerfield & CEO,
Aviko Radiopharmaceuticals*

Beverly Lu, Ph.D., *Investor, Yosemite*

Marie-Claire Peakman, Ph.D., *Pfizer Ventures & Executive Director,
Emerging Science & Innovation*

Fei Shen, Ph.D., *Managing Director, BI Venture Fund*

4:10 PM – 6:00 PM INTERMISSION BREAK



Matt Tremblay, Ph.D.



Dave Greenwald, Ph.D.



Beverly Lu, Ph.D.



Marie-Claire Peakman, Ph.D.



Fei Shen, Ph.D.

Part IV: Reception, Dinner and Award Ceremony

(Black-tie Optional)

6:00 PM – 7:00 PM COCKTAIL RECEPTION

7:00 PM – 9:00 PM DINNER AWARD AND PRESENTATION



HONORING

Dennis J. Slamon, M.D., Ph.D.

EMCEE

Kristen Berset-Harris, *Host of Great Day Washington, WUSA9*

OPENING REMARKS

Sujuan Ba, Ph.D., CEO of NFCR, Co-Founder of AIM-HI Accelerator Fund
Co-Chair of 2024 Szent-Györgyi Prize Selection Committee

INTRODUCTION OF KEYNOTE SPEAKER

Azra Raza, M.D., *Chan Soon-Shiong Professor of Medicine, Columbia University in New York*

KEYNOTE PRESENTATION

Siddhartha Mukherjee, M.D., 2011 Pulitzer Prize Winner, Associate Professor of Medicine,
Columbia University Irving Medical Center, Columbia University

INTRODUCTION OF THE 2024 SZENT-GYÖRGYI PRIZE WINNER

Isaac Witz, Ph.D., Professor Emeritus at Tel Aviv University
Chair of 2024 Szent-Györgyi Prize Selection Committee and 2023 Szent-Györgyi Prize Winner



Kristen Berset-Harris



Sujuan Ba, Ph.D.



Azra Raza, M.D.



Siddhartha Mukherjee, M.D.



Isaac Witz, Ph.D.

Part IV: Reception, Dinner and Award Ceremony

(Black-tie Optional)

PRESENTATION OF THE 2024 SZENT-GYÖRGYI PRIZE WINNER



Dennis J. Slamon, M.D., Ph.D.

***Professor of Medicine, Director of Clinical and Translational Research
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA***

Dr. Dennis J. Slamon is honored for his pioneering contributions to the field of oncology, particularly his groundbreaking work in the development of targeted therapies for breast cancer. His relentless dedication to understanding the molecular mechanisms of cancer has revolutionized the treatment of HER2-positive breast cancer, transforming what was once a deadly diagnosis into one with significantly improved outcomes.

In 1987, he discovered that the amplification of the growth-promoting HER2 gene led to the pathologic over-expression of the gene product and its association with 25-30% of human breast cancer. This alteration, a non-inherited mutation, defined a new subtype of breast cancer and challenged the prevailing notion that cancers with similar histology were biologically the same.

With unwavering determination, Dr. Slamon demonstrated that antibodies targeting HER2 receptors inhibited cell growth both in vitro and in vivo. He played a pivotal role in the clinical development of HER2-targeted antibodies, from preclinical studies to proof-of-concept trials and ultimately to the U.S. FDA approval of Trastuzumab (Herceptin) in 1998. Trastuzumab has since been used to treat nearly 3 million women with HER2-positive breast cancer worldwide. Dr. Slamon's efforts not only reversed the prognosis for HER2-positive breast cancers but also established a new paradigm for cancer treatment – targeting the molecular mechanisms driving the disease.

Dr. Slamon also made significant strides in the treatment of estrogen receptor (ER) positive but HER2-negative breast cancers, which is 65% of breast cancer diagnoses. He discovered that this major breast cancer subtype is uniquely sensitive to inhibitors of enzymes crucial to cell division, the cyclin-dependent kinases 4 and 6. This discovery and his translational research led to clinical trials and the 2015 approval of the initially targeted inhibitor of CDK-4/6, palbociclib, significantly improving the prognosis for the most common type of high-risk breast cancer from poor outcomes to one of lives saved.

Dr. Slamon's work continues to push the boundaries of cancer research as he investigates resistance mechanisms to HER2-targeted therapies and explores the biology of other breast cancer subtypes. His contributions have not only saved countless lives but also reshaped the landscape of cancer treatment, offering hope and new possibilities for patients around the world.

Part IV: Reception, Dinner and Award Ceremony

(Black-tie Optional)

PANEL DISCUSSION: LIVE FROM THE NATIONAL PRESS CLUB

PANELISTS:

Dennis Slamon, M.D., Ph.D., *Professor of Medicine, Director of Clinical and Translational Research
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA*

Margaret Foti, Ph.D., M.D., (hc) *CEO, American Association for Cancer Research*

Siddhartha Mukherjee, M.D., *2011 Pulitzer Prize Winner, Associate Professor of Medicine,
Columbia University Irving Medical Center, Columbia University*

Olufunmilayo Olopade, M.D., *Walter L. Palmer Distinguished Service Professor of Medicine, Professor of
Human Genetics, Director of Center for Clinical Cancer Genetics and Global Health, The University of Chicago*

Mohit Manrao, MBA, *SVP AstraZeneca, Head of US Oncology*
Cancer Research Advocates: Shereen and Isabella Pavlides



**Dennis J. Slamon,
M.D., Ph.D.**



**Margaret Foti, Ph.D.,
M.D. (hc)**



Siddhartha Mukherjee, M.D.



**Olufunmilayo (Funmi)
Olopade, M.D.**



Mohit Manrao, MBA



Shereen Pavlides



Isabella Pavlides

CLOSING REMARKS

Alfred Slanetz, Ph.D., *Board Chair of NFCR*



Alfred Slanetz, Ph.D.

Congratulations on
receiving the coveted
**2024 Szent-Györgyi
Prize for Progress
in Cancer Research**



Dennis J. Slamon, M.D., Ph.D.

Professor of Medicine

Director of Clinical and Translational Research

Thank you for your visionary leadership and groundbreaking contributions over the years that have reshaped cancer treatment and transformed patient outcomes. The advancements you pioneered in breast cancer research have not only altered the course of the disease but also opened the door to a new generation of targeted therapies, setting a global standard in oncology. The impact of your discoveries is evident in the millions of lives improved around the world.

UCLA Health

**Jonsson Comprehensive
Cancer Center**

ACCELERATING DISCOVERIES TO PREVENT AND CURE CANCER

About the AIM-HI Beacon Award for Women Leaders in Oncology

The AIM-HI Beacon Award for Women Leaders in Oncology was established in 2022 by the AIM-HI Accelerator Fund and sponsored by the National Foundation for Cancer Research (NFCR). This award recognizes outstanding women pioneers in all sectors of the health and life sciences industry who have made a significant impact on advancing cancer treatment, detection, and diagnosis for patients worldwide through the development and commercialization of novel technologies, advocacy, and/or implementation of public policy.

In 2022, the first AIM-HI Beacon Award winner, Anna D. Barker, Ph.D., was honored for implementing often unprecedented scientific and clinical programs, most notably The Cancer Genome Atlas (TCGA) and the GBM AGILE, that enabled advances in cancer research and provided critical support to develop precision oncology. Last year, 2023, the second AIM-HI Beacon Award winner, Monica M. Bertagnolli, M.D., was honored for her collaborative initiatives to transform data infrastructure for clinical research. Dr. Bertagnolli brought together partners and resources from different sectors to launch groundbreaking efforts in cancer prevention and early detection, a national navigation program for childhood cancers, and additional programs to bring clinical trials to more Americans.

NOMINATIONS ARE ASSESSED ACCORDING TO THE FOLLOWING CRITERIA

The Beacon Award Selection Committee unanimously voted for Dr. Margaret Foti to receive the 2024 AIM-HI Beacon Award for Women Leaders in Oncology



- Sustained commitment and leadership for cancer research, development and commercialization of innovative products
- Advocacy for and implementation of public policy to benefit cancer patients
- Encouragement, advocacy and inspiration of other women
- Impact on cancer patients, their families and community

The AIM-HI Accelerator Fund thanks the members of the Committee for their dedication to the success of 2024 AIM-HI Beacon Award for Women Leaders in Oncology

About the AIM-HI Beacon Award for Women Leaders in Oncology

2024 AIM-HI BEACON AWARD SELECTION COMMITTEE

Sujuan Ba, Ph.D.

*Co-Chair, CEO & Co-Founder, AIM-HI Accelerator Fund
President & CEO, National Foundation for Cancer Research*

Webster K. Cavenee, Ph.D.

Co-Chair, Distinguished Professor Emeritus, University of California San Diego

Bahija Jallal, Ph.D.

CEO & Director of the Board, Immunocore

Raju Kucherlapati, Ph.D.

Paul C. Cabot Professor of Genetics & Professor of Medicine, Harvard Medical School

Patricia Obermaier, MBA

Chief Growth Officer, Global Health and Life Sciences, Microsoft

Libia Scheller, Ph.D., MBA

*Global Head Oncology-Cooperative Groups & Strategic Alliances,
Bayer Health Care Pharmaceuticals*

Thea Tlsty, Ph.D.

*Professor, Department of Pathology and Director of the Center for Translational Research
in the Molecular Genetics of Cancer, UCSF*

PREVIOUS AIM-HI BEACON AWARD WINNERS



Monica M. Bertagnolli, M.D.

2023 Winner

*Director, National Institutes of Health
and Past Director, National Cancer
Institute*



Anna D. Barker, Ph.D.

2022 Winner

*Chief Strategy Officer, Ellison Institute
for Transformative Medicine
Distinguished Visiting Fellow, Complex
Adaptive Systems, Arizona State
University Biosciences*

About the AIM-HI Women's Venture Competition

The AIM-HI Accelerator Fund, in collaboration with the National Foundation for Cancer Research and the Asian Fund for Cancer Research, launched the Women's Venture Competition in 2020. This one-of-a-kind annual competition provides women-led oncology startups with lifeline seed funding, critical coaching, and continuous access to our global network.

AIM-HI has established a rigorous and unparalleled three-part review and due diligence process to select the most deserving candidates. AIM-HI thanks the members of the Selection, Judging and Investment Committees for their dedication to the success of the 2024 Competition.

We are deeply grateful to Wilson Sonsini Goodrich & Rosati and Qral Group for their pro bono services and critically-needed support.

2024 WOMEN'S VENTURE COMPETITION COMMITTEE (ALPHABETICAL ORDER)

Anna D. Barker, Ph.D., *Chief Strategy Officer, Lawrence J. Ellison Institute of Technology*

Webster K. Cavenee, Ph.D., *Distinguished Professor Emeritus, University of California San Diego*

Aleksandra Filipovic, M.D., Ph.D., *Head of Oncology, PureTech Health*

Pamela Garzone, Ph.D., *Chief Development Officer, Anixa Biosciences*

Dimitra Georganopoulou, Ph.D., *General Partner, Qral Ventures*

Gary Gordon, M.D., Ph.D., *Senior Medical Advisor and Board Member, Global Coalition for Adaptive Research*

Daniel Johnson, Ph.D., *Professor and Vice Chair of Research, Department of Otolaryngology-Head and Neck Surgery (OHNS), University of California San Francisco*

Raju Kucherlapati, Ph.D., *Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School*

Matthew Lawler, *Entrepreneur-In-Residence, Blackbird Laboratories*

Brian Leyland-Jones, MBBS, Ph.D., *Chief Medical Officer, National Foundation for Cancer Research*

Scott Lippman, M.D., *Distinguished Professor of Medicine & Associate Vice Chancellor for Cancer Research, UC San Diego Health*

Jimmy Lu, JD, MBA, *Co-Founder and Managing Director, Eos BioInnovation*

Eva Martin, M.D., *Senior Director, Alliance and Asset Management, Roche Pharma Partnering*

Kornelia Polyak, M.D., Ph.D., *Professor of Medicine, Dana-Farber Cancer Institute*

Michael Salgaller, Ph.D., *Supervisory Invention Development & Marketing Specialist, National Institutes of Health/National Cancer Institute*

Libia F. Scheller, Ph.D., MBA, *Global Head Oncology-Cooperative Groups & Strategic Alliances, Bayer Health Care Pharmaceuticals*

Fei Shen, Ph.D., *Managing Director, Boehringer Ingelheim Venture Fund USA*

Matt Tremblay, Ph.D., *CEO, Blackbird Laboratories*

About the AIM-HI Women's Venture Competition

PREVIOUS WOMEN VENTURE COMPETITION WINNERS



Sarah Hein, Ph.D.
2023 First Prize Winner
*Co-Founder & CEO,
March Biosciences*



Johanna Webb
2022 First Prize Winner
*President & CEO,
RiverWalk Therapeutics*



María Varela
2021 First Prize Winner
*CEO,
ARDAN PHARMA*



Manijeh Goldberg, Ph.D.
2020 First Prize Winner
*CEO,
Privo Technologies*



About the Szent-Györgyi Prize for Progress in Cancer Research



ALBERT SZENT-GYÖRGYI, M.D., PH.D.

*Co-Founder, National Foundation for Cancer Research
1937 Nobel Laureate in Philosophy and Medicine*

***“Discovery is seeing what everybody else has seen,
and thinking what nobody else has thought.”***

The National Foundation for Cancer Research is proud to present the Szent-Györgyi Prize for Progress in Cancer Research to honor outstanding scientists whose seminal discovery or pioneering body of work has contributed to cancer prevention, diagnosis, or treatment and has had a lasting impact on understanding cancer, holding the promise of improving or saving the lives of cancer patients.

This annual prize is named in memory of Dr. Albert Szent-Györgyi, who was a pioneer, and, like many other explorers, he challenged the conventional thinking of the day to pursue his novel and promising ideas. After winning the Nobel Prize for his study on vitamin C and cell respiration, Dr. Szent-Györgyi set his sights on finding a way to defeat cancer.

Beyond his laboratory, Dr. Szent-Györgyi was a leading advocate for developing resources to provide scientists with the financial support necessary to pursue novel cancer research ideas. In 1973, he changed the face of cancer research funding by co-founding NCFR with entrepreneur Franklin C. Salisbury. Since then, NCFR has provided more than \$415 million in support of cancer research and prevention education programs.

The Szent-Györgyi Prize serves to stimulate continued investment in pioneering research that will produce scientific breakthroughs. It intends to deepen the understanding of the underlying basis of cancer and the translation of this knowledge to improve the lives of cancer patients.

By calling attention annually to achievements in this area, it is the goal of the Szent-Györgyi Prize to heighten awareness of the research and the discovery that leads to new cancer treatments and cancer cures. The Prize also promotes public awareness of the importance of basic cancer research and the need to accelerate the translation of these research discoveries into new cancer treatments.

2024 Szent-Györgyi Prize Selection Committee

THE SZENT-GYÖRGYI PRIZE FOR PROGRESS IN CANCER RESEARCH



The Szent-Györgyi Prize Selection Committee has been established to advise and consult with the National Foundation for Cancer Research on each year's pool of Prize nominees.

Nominations are reviewed and evaluated based on the following criteria:

- A seminal discovery or pioneering body of work that has contributed to cancer prevention, diagnosis, or treatment.
- Has had a lasting impact on understanding cancer, holding the promise of improving or saving the lives of cancer patients.

2024 SZENT-GYÖRGYI PRIZE SELECTION COMMITTEE

Isaac Witz, Ph.D., *Chair, Tel Aviv University (2023 Szent-Györgyi Prize winner)*

Sujuan Ba, Ph.D., *Co-Chair, National Foundation for Cancer Research*

Webster K. Cavenee, Ph.D., *Ludwig Institute for Cancer Research, University of California San Diego (2007 Szent-Györgyi Prize winner)*

Carlo M. Croce, M.D., *The Ohio State University (2008 Szent-Györgyi Prize winner)*

Michael N. Hall, Ph.D., *Biozentrum of the University of Basel (2017 Szent-Györgyi Prize winner)*

Mary-Claire King, Ph.D., *University of Washington School of Medicine (2016 Szent-Györgyi Prize winner)*

Raju Kucherlapati, Ph.D., *Harvard Medical School*

Funmi Olopade, M.D., *The University of Chicago*

Leona Samson, Ph.D., *Massachusetts Institute of Technology*

Catherine Sautès-Fridman, Ph.D., *University of Paris Cité*

John T. Schiller, Ph.D., *National Cancer Institute (2018 Szent-Györgyi Prize winner)*

Jeffrey Schlom, Ph.D., *National Cancer Institute*

Peter K. Vogt, Ph.D., *Scripps Research (2010 Szent-Györgyi Prize winner)*

The National Foundation for Cancer Research thanks the members of the Committee for their dedication to the success of 2024 Szent-Györgyi Prize for Progress in Cancer Research

Previous Szent-Györgyi Prize Winners



Isaac P. Witz, Ph.D.
2023 Winner
Tel Aviv University



Rakesh K. Jain, Ph.D.
2022 Winner
Harvard Medical School &
Massachusetts General Hospital



Mark M. Davis, Ph.D.
2021 Co-Winner
Stanford University School
of Medicine



Tak W. Mak, Ph.D.
2021 Co-Winner
University of Toronto; Princess
Margaret Cancer Centre



Susan Band Horwitz, Ph.D.
2020 Winner
Albert Einstein College
of Medicine, Bronx, New York



**Steven A. Rosenberg,
M.D., Ph.D.**
2019 Winner
National Cancer Institute



Douglas R. Lowy, M.D.
2018 Co-Winner
National Cancer Institute



John T. Schiller, Ph.D.
2018 Co-Winner
National Institute Health



Michael N. Hall, Ph.D.
2017 Winner
Biozentrum of the University
of Basel, Switzerland



Mary-Claire King, Ph.D.
2016 Winner
University of Washington



Frederick W. Alt, Ph.D.
2015 Winner
Harvard Medical School & Boston
Children's Hospital



James P. Allison, Ph.D.
2014 Winner
The University of Texas, MD
Anderson Cancer Center, Houston



Alex Matter, M.D.
2013 Winner
Agency for Science, Technology
and Research(A*STAR), Singapore



Zhen-Yi Wang, M.D.
2012 Co-Winner
Shanghai Jiao Tong University



Zhu Chen, M.D., Ph.D.
2012 Co-Winner
Shanghai Jiao Tong University



Beatrice Mintz, Ph.D.
2011 Winner
Fox Chase Cancer Center,
Philadelphia



Peter K. Vogt, Ph.D.
2010 Winner
Scripps Research La Jolla



**Ronald A. DePinho,
M.D.**
2009 Winner
The University of Texas, MD
Anderson Cancer Center,
Houston



Carlo M. Croce, M.D.
2008 Winner
The Ohio State University



**Webster K. Cavenee,
Ph.D.**
2007 Winner
University of California,
San Diego



Harold F. Dvorak, M.D.
2006 Winner
Harvard Medical School
and Beth Israel Deaconess
Medical Center, Boston



AIM-HI
ACCELERATOR FUND
WE DRIVE CURES FORWARD

FUELING INNOVATION:

Support the Next Generation of Cancer Treatments

The **AIM-HI Accelerator Fund** is a key player in the global network dedicated to transforming innovative cancer discoveries into life-saving treatments. Established in 2019 with support from the National Foundation for Cancer Research, AIM-HI accelerates the development of cancer drug discoveries by investing in seed-stage oncology companies. By bridging the gap between groundbreaking research and impactful cancer therapies, AIM-HI cultivates a powerful ecosystem for early-stage companies and entrepreneurs.

Your support can fuel the next wave of cancer treatment breakthroughs. Partner with AIM-HI to advance promising innovations and bring new therapies to patients around the world.

**INVEST IN THE FUTURE
OF CANCER TREATMENT
AND BE PART OF THE CURE.**



THE GLOBAL NETWORK
COLLABORATION TO CURE CANCER



aim-hiaccelerator.org

THANK YOU FOR YOUR GENEROUS SUPPORT!

PLATINUM SPONSORS



Blackbird Labs — named for the knowledge-seeking birds of lore and an homage to the Baltimore Ravens — is an independent, nonprofit research platform founded in 2023. Blackbird Labs launched with a \$100 million founding grant from The Stephen and Renee Bisciotti Foundation and research collaborations with Johns Hopkins University, the University of Maryland, Baltimore, and the Lieber Institute for Brain Development. Blackbird Labs' mission is to help universities and investigators commercialize their academic research to build innovative companies and bring world-changing technologies to life. Our vision is to catalyze a thriving entrepreneurial ecosystem in Baltimore by building innovative biotechnology companies. Blackbird Labs helps catalyze Baltimore's life sciences research by supporting start-up formation and development. Our goal is to commercialize the transformational science from our local partner institutions and drive impact across the ecosystem and on a national scale.



AstraZeneca is a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society, and the planet. With the business goal to deliver growth through innovation strategy and achieve the purpose of pushing the boundaries of science to deliver life-changing medicines, our strategy covers sectors of science & innovation, growth & therapy area leadership, global footprint, and sustainability. The company's purpose and values are inspired by our Values and what science can do, and we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients, society, and our shareholders. AstraZeneca is committed to operating sustainably, in a way that recognises the interconnection between business growth, the needs of society, and the limitations of our planet.



Help Us Bring Forth the

Future of Biomedicine

Blackbird Labs helps catalyze Baltimore's life sciences research by supporting start-up formation and development. Our goal is to commercialize the transformational science from our local academic partners and drive impact across the ecosystem and on a national scale.

BLACKBIRDLAB.ORG | INFO@BLACKBIRDLAB.ORG

AstraZeneca 

*We are leading
a revolution to
transform
cancer care.*



TOGETHER, WE MAKE CURES POSSIBLE!

GOLD SPONSORS



American Association
for Cancer Research®



AIM+HI
ACCELERATOR FUND
WE DRIVE CURES FORWARD



AFCR
Asian Fund for Cancer Research Limited
亞洲癌症研究基金會有限公司

SILVER SPONSORS



where ideas originate



Health

Jonsson Comprehensive
Cancer Center

BRONZE SPONSORS



A MOORE COMPANY

STRATEGIC PARTNERS



Together we advance



PARTNER SPONSORS



From here. For here.



Additional Thank You to our supporters:

Gilead Sciences, Inc., Janssen/J&J, and an independent education grant from Pfizer



Advancing Cancer Breakthroughs for Asia and the World: Be Part of the Global Solution

The **Asian Fund for Cancer Research (AFCR)** plays a vital role in the global network working to combat cancers that disproportionately affect Asian populations. With headquarters in Hong Kong and a global reach, AFCR is uniquely positioned to explore the genetic and molecular factors behind cancer in Asian demographics. Through collaborations with international partners, AFCR accelerates groundbreaking research and advances new therapies, bringing hope to cancer patients across Asia and beyond.

Your support can drive these innovations even further. By partnering with AFCR, you can help shape the future of cancer research and contribute to life-saving solutions. Together, we can develop targeted therapies that make a lasting impact on patients worldwide.

**JOIN US IN ADVANCING GLOBAL CANCER
RESEARCH AND BE PART OF THE CURE.**



[AFCR.org](https://www.afcr.org)

THE GLOBAL NETWORK
COLLABORATION TO CURE CANCER





THE GLOBAL NETWORK

COLLABORATION TO CURE CANCER

Learn more about our work



www.nfcr.org www.aim-hiaccelerator.org www.afcr.org
